Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review.

Mathieu GauthéPaul SargosEric BarretGaëlle Fromont-HankardJean-Baptiste BeauvalLaurent BrureauGilles CréhangeRaphaële Renard-PennaCharles Dariane Gaëlle FiardRomain MathieuGuilhem RoubaudAlain RuffionMorgan RouprêtGuillaume Ploussardnull On Behalf Of The Cc-Afu

Published in: Journal of clinical medicine (2021)

Theranostics in nuclear medicine will continue to develop in the future, especially for PCa patients. Targets other than PSMA exist and deserve to be promoted.

Keyphrases

prostate cancer
pet ct
end stage renal disease
ejection fraction
pet imaging
newly diagnosed
chronic kidney disease
peritoneal dialysis
patient reported outcomes